Skip to main content
SpringerLink
Log in

Neuroprotective Effects of MAO-B Inhibition: Clinical Studies in Parkinson’s Disease

  • Chapter
Inhibitors of Monoamine Oxidase B

Part of the book series: Milestones in Drug Therapy ((MDT))

Abstract

Parkinson’s Disease (PD), characterized by a marked loss of nigrostriatal neurons [1], is generally a disorder of progressive disability. While additional neuronal systems of the PD brain are altered [2], the change most closely linked to the clinical symptomatology of Parkinsonism is the impaired generation of striatal dopamine. Dopamine production may also figure in the special vulnerability of substantia nigra pars compacta neurons in PD. Several hypotheses for the decline in dopaminergic neurons have been advanced. One speculation has been that one or more exogenous toxins might produce a metabolic effect damaging these neurons. Several neurotoxins with highly specific actions against nigrostriatal dopaminergic neurons are known. These produce parkinsonian symptomatology both in animal models and, in the case of manganese and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), in man. MPTP has been the most intriguing of these because of its need for conversion in the brain prior to exerting toxicity to nigrostriatal dopamine neurons via their mitochondrial metabolism. The unique properties of MPTP have provided grist for speculation that PD could conceivably be the outcome of intermittent or continuous neurotoxicity from exposure to similar types of compounds [3–5].

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 49.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 69.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Forno LS. Pathology of Parkinson’s disease: the importance of the substantia nigra and Lewy bodies. In: Stern GM, editor. Parkinson’s Disease. Baltimore: Johns Hopkins Press 1990; 185–238.

    Google Scholar 

  2. Agid Y, Javoy-Agid F, Ruberg M. Biochemistry of neurotransmitters in Parkinson’s disease. In: Marsden CD, Fahn S, editors. Movement Disorders 2 . London: Butterworths 1987; 166–230.

    Google Scholar 

  3. Cohen G. Monoamine oxidase, hydrogen peroxide, and Parkinson’s Disease. Adv Neurol 1986; 45: 119–125.

    Google Scholar 

  4. Kopin IJ, Markey SP. MPTP toxicity: implications for research in Parkinson’s disease. Ann Rev Neurosci 1988; 11: 81–96.

    Article  Google Scholar 

  5. Ballard PA, Tetrud JW, Langston JW. Permanent human parkinsonism due to 1-methyl- 4-phenyl-l,2,3,6-tetrahydropyridine (MPTP): seven cases. Neurology 1985; 35: 949–956.

    Article  Google Scholar 

  6. Fornstedt B, Brun A, Rosengren E, Carlsson A. The apparent autoxidation rate of catechols in dopamine-rich regions of human brains increases with the degree of depigmentation of substantia nigra. J Neural Transm [P-D Sect] 1989; 1: 279–295.

    Article  Google Scholar 

  7. Spina MB, Cohen G. Exposure of striatal synaptosomes to L-dopa increases levels of oxidized gluthathione. J Pharmacol Exptl Therap 1988; 247: 502–507.

    Google Scholar 

  8. Halliwell B. Oxidants and the central nervous system: some fundamental questions. Acta Neurol Scand 1989; 126: 23–33.

    Article  Google Scholar 

  9. Adams JD, Odunze IN. Oxygen free radicals and Parkinson’s Disease. Free Radical Biol Med 1991; 10: 161–169.

    Article  Google Scholar 

  10. Halliwell B, Gutteridge JMC. Free Radicals in Biology and Medicine. Oxford: 1989; Oxford Press.

    Google Scholar 

  11. Mogi M, Harada M, Kiuchi K, Kojima K, Kondo T, Narabayashi H, Rausch D, Riederer P, Jellinger K, Nagatsu T. Homospecific activity (activity per enzyme protein) of tyrosine hydroxylase increases in Parkinson’s Disease. J Neural Transm 1988; 72: 77–81.

    Article  Google Scholar 

  12. Hornykiewicz O, Kish SJ. Biochemical pathophysiology of Parkinson’s Disease. Adv Neurol 1986; 45: 19–34.

    Google Scholar 

  13. Cohen G, Spina BM. Deprenyl suppresses the oxidant stress associated with increased dopamine turnover. Ann Neurol 1989; 26: 689–690.

    Article  Google Scholar 

  14. Kato T, Dong E, Iskii K, Kinemuchi H. Brain dialysis. In vivo metabolism of dopamine and serotonin by monoamine oxidase A but not B in the striatum of unrestrained rats. J Neurochem 1986; 48: 1277–1282.

    Article  Google Scholar 

  15. Dexter DT, Wells FR, Lees AJ, Agid Y, Jenner P, Marsden CD. Increased nigral iron content and alterations in other metals occurring in brain in Parkinson’s disease. J Neurochem 1989; 52: 1830–1836.

    Article  Google Scholar 

  16. Riederer P, Sofic E, Rausch WD et al. Transition metals, ferritin, glutathione, and ascorbic acid in parkinsonian brains. J Neurochem 1989; 52: 515–520.

    Article  Google Scholar 

  17. Knoll J. The striatal dopamine dependency of life span in male rats. Longevity study with (-)deprenyl. Mech Ageing Devel 1988; 46: 237–262.

    Article  Google Scholar 

  18. Birkmayer W, Knoll J, Riederer P, Youdim MBH, Hars V, Marton J. Increased life-expectancy resulting from the addition of l-deprenyl to Madopar treatment in Parkinson’s disease: a longterm study. J Neural Transm 1985; 65: 113–127.

    Article  Google Scholar 

  19. The Parkinson Study Group: DATATOP: a multicenter controlled clinical trial in early Parkinson’s disease. Arch Neurol 1989; 46: 1052–1060.

    Article  Google Scholar 

  20. Le Witt PA, The Parkinson Study Group. Deprenyl’s protective effect against the progression of Parkinson’s Disease: the DATATOP study. Acta Neurol Scand 1991; 84 (Supplement 136): 79–86.

    Google Scholar 

  21. Riederer P, Youdim MB. Monoamine oxidase activity and monoamine metabolism in brains of parkinsonian patients treated with l-deprenyl. J Neurochem 1986; 46: 1359–1365.

    Article  Google Scholar 

  22. Golbe LI. Deprenyl as symptomatic therapy in Parkinson’s disease. Clin Neuropharma- col 1988; 11: 387–400.

    Article  Google Scholar 

  23. The Parkinson Study Group. Effect of deprenyl on the progression of disability in early Parkinson’s disease. N Engl J Med 1989; 321: 1364–1371.

    Article  Google Scholar 

  24. Tetrud JW, Langston JW. The effect of deprenyl (selegiline) on the natural history of Parkinson’s disease. Science 1989; 145: 519–522.

    Article  Google Scholar 

  25. Elizan TS, Yahr MD, Moros DA, Mendoza MR, Pang S, Bodian CA. Selegiline use to prevent progression of Parkinson’s disease. Experience in 22 de novo patients. Arch Neurol 1989; 46: 1275–1279.

    Article  Google Scholar 

  26. Teräväinen H. Selegiline in Parkinson’s disease. Acta Neurologica Scand 1990; 81: 333–336.

    Article  Google Scholar 

  27. Allain H, Cougnard J, Neukirch H-C, French Selegiline Multicenter Trial Members. Selegiline in de novo parkinsonian patients: The French Selegiline multicenter trial. Acta Neurol Scand 1991; 84 (Supplement 136): 73–78.

    Article  Google Scholar 

  28. Myllylä VV, Sotaniemi KA, Vuorinen JA, Heinonen EH. Selegiline as a primary treatment of Parkinson’s disease. Acta Neurol Scand 1991; 84 (Supplement 136): 70–72.

    Article  Google Scholar 

  29. LeWitt PA, Galloway MP, Matson W, Milbury P, McDermott M, Oakes D, The Parkinson Study Group. Markers of endogenous dopamine synthesis in Parkinson’s Disease. Neurology 1992; 42 (Supplement 3): 420.

    Google Scholar 

  30. Antelman SM, Edwards DJ, Lin M. Phenylethylamine: evidence for a direct, postsynaptic dopamine-receptor stimulatory action. Brain Res 1977; 127: 317–322.

    Article  Google Scholar 

  31. Jackson DM. 2-phenylethylamine, dopamine, and behaviour. In: Sandler M, Dahlstrom A, Belmaker RH, editors. Progress in catecholamine research. Part B: Central aspects. New York: Alan R Liss 1988; 429–432.

    Google Scholar 

  32. Robinson TE, Becker JB. Enduring changes in brain and behavior produced by chronic amphetamine administration: a review and evaluation of animal models of amphetamine psychosis. Brain Res Rev 1986; 11: 157–198.

    Article  Google Scholar 

  33. Tatton WG, Greenwood CE. Rescue of dying neurons: a new action for deprenyl in MPTP parkinsonism. J Neurosci Res 1991; 30: 666–672.

    Article  Google Scholar 

  34. Da Prada M, Kettler R, Keller HH et al. From moclobemide to Ro 19–6327 and Ro 41–1049: the development of a new class of reversible, selective MAO-A and MAO-B inhibitors. J Neural Transm 1990; 29 (Supplement): 279–292.

    Google Scholar 

  35. LeWitt PA, Galloway MP. Neurochemical markers of Parkinson’s Disease. In: Koller WC, Paulson G, editors. Therapy of Parkinson’s Disease. New York: Marcel Dekker 1990; 63–93.

    Google Scholar 

  36. Hyman C, Hofer M, Barde Y-A et al. BDNF is a neurotrophic factor for dopaminergic neurons of the substantia nigra. Nature 1990; 350: 230–232.

    Article  Google Scholar 

Download references

Authors
  1. P. A. LeWitt
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Dept. of Pharmacology, ASTA Medica AG, Weismüllerstrasse 45, D-6000, Frankfurt/Main 1, Germany

    I. Szelenyi

Rights and permissions

Reprints and permissions

Copyright information

© 1993 Springer Basel AG

About this chapter

Cite this chapter

LeWitt, P.A. (1993). Neuroprotective Effects of MAO-B Inhibition: Clinical Studies in Parkinson’s Disease. In: Szelenyi, I. (eds) Inhibitors of Monoamine Oxidase B. Milestones in Drug Therapy. Birkhäuser, Basel. https://doi.org/10.1007/978-3-0348-6348-3_15

Download citation

  • DOI: https://doi.org/10.1007/978-3-0348-6348-3_15

  • Publisher Name: Birkhäuser, Basel

  • Print ISBN: 978-3-0348-6349-0

  • Online ISBN: 978-3-0348-6348-3

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation